<DOC>
	<DOCNO>NCT00374075</DOCNO>
	<brief_summary>This open label phase I/II clinical trial ass safety , tolerability potential effect SMN mRNA protein vivo compound preliminary evidence support potential effect SMN level vitro .</brief_summary>
	<brief_title>Study Safety Dosing Effect SMN Levels Valproic Acid ( VPA ) Patients With Spinal Muscular Atrophy</brief_title>
	<detailed_description>This open label phase I/II trial valproic acid 40 SMA subject &gt; 2 year age severe , intermediate , mild phenotype . Primary outcome measure include laboratory physical examination assessment monitor effect liver , hematologic , metabolic nutritional status . Secondary outcome include measure gross motor function ; electrophysiologic measure denervation ; DEXA estimate body composition , bone mineral density content ; measure pulmonary function ; quantitative SMN mRNA protein level blood cell . Subjects need 2-3 baseline visit 3 -6 month period prior enrollment . Follow-up visit schedule 3 , 6 12 month treatment .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Patients must diagnosis SMA , confirm genetic test Only patient 2 year age old enrollment eligible Patients take medication know hepatotoxicity , congenital metabolic disorder multiple anticonvulsant medication Patients take medication may interact VPA Patients ventilatory support 16 hour per day Patients currently enrol treatment trial</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Spinal Muscular Atrophy ( SMA )</keyword>
	<keyword>Valproic Acid</keyword>
</DOC>